Vivek Mittal, PhD

Associate Affiliate Member, Research Institute
Houston Methodist


Vivek Mittal is the director of the Neuberger Berman Foundation Lung Cancer Laboratory and an associate professor of Cell and Developmental Biology in the cardiothoracic surgery department at Weill Cornell Medical College in New York.

Previously, Dr. Mittal held faculty appointments at Cold Spring Harbor Laboratory and State University of New York, Stony Brook. Dr. Mittal speaks at public engagements to diverse audiences around the world and has produced several patents and authored articles in leading journals including Science, Nature, Cancer Cell, PNAS, and other leading peer-reviewed journals and text books. He contributes to NIH study sections and has chaired sessions at prominent national conferences and symposiums. His research is supported by funds from the National Cancer Institute and private foundations.

As a director of research at the Lung Cancer Center, Dr. Mittal oversees the development of future research themes and educational activities to ensure their concordance with the overall translational mission of the Center. He created a state-of-the art Biobank at Weill Cornell Medical College as a repository for biospecimens from lung cancer, other thoracic malignancies, and benign diseases.

Dr. Mittal is committed to the mentoring of the clinical fellows and faculty in basic research, which is a critical part of the training of the next generation of translational researchers. He is an active teacher and mentor, organizing focus groups and supervising a problem based learning course for medical students. He mentors graduate students, postdoctoral fellows, surgical fellows and junior faculty. He is also dedicated to interviewing candidates for admission to the M.D. and Ph.D. program, and recruitment of junior faculty.

Description of Research

Research in Dr. Mittal’s lab studies de novo lung carcinogenesis, as well as the initiation and progression of metastatic lesions derived from extrapulmonary neoplasms. The program integrates clinical and basic science to foster innovative research for the prevention, detection, and treatment of cancer.

A major aim of his research is to understand cancer cell intrinsic and extrinsic programs that regulate tumor growth and metastasis. Cancer cell intrinsic programs include aberrant signaling pathways, which are investigated at several levels of regulation including transcriptional, epigenetic, and small regulatory RNAs. Cancer cell extrinsic programs include the contribution of the tumor microenvironment. The heterotypic reciprocal signaling between the stromal cells and tumor epithelial compartments that contribute to tumor progression can be unraveled by dissecting the complexity of various stromal cell types that comprise the microenvironment. Dr. Mittal is interested in understanding how these two programs are integrated to regulate key tumorigenic processes including angiogenesis, inflammation, epithelial to mesenchymal transition, therapeutic resistance, metastasis initiation and progression.

Dr. Mittal’s research has produced novel stromal targets for prognosis and drug design. A major goal of this ongoing work is to collaborate with clinicians to rapidly validate additional molecular research findings in preclinical and clinical studies, and determine if they have diagnostic and therapeutic potential for clinical use.

Key contributions include:
-First demonstration that endothelial progenitor cells promote angiogenesis necessary for the formation of lethal macrometastases (Science, 2008).
-First demonstration that myeloid cells induce mesenchymal to epithelial transition that promotes breast cancer metastasis to the lungs (Cancer Research, 2012).
-Discovered microRNA-708, which is epigenetically silenced during metastatic progression in breast cancer (Cancer Cell, 2013 in press). Currently, the potential of miR-708 as a therapeutic against triple negative breast cancer is being evaluated.
-Have identified a novel mechanism, whereby metastasis-incompetent tumors generate metastasis-suppressive niches that inhibit metastasis (in review, Cancer Discovery).
-Analysis of fresh clinical samples have led to the discovery of novel stromal targets of prognostic and therapeutic value in lung cancer.

Areas Of Expertise

Breast cancer Tumor microenvironment microRNA Lung cancer Genomics Epigenome Mouse models
Education & Training

MS, Jawaharlal Nehru University
PhD, Jawaharlal Nehru University

Global evolution of the tumor microenvironment associated with progression from preinvasive invasive to invasive human lung adenocarcinoma
Altorki, NK, Borczuk, AC, Harrison, S, Groner, LK, Bhinder, B, Mittal, V, Elemento, O & McGraw, TE 2022, , Cell Reports, vol. 39, no. 1, 110639. https://doi.org/10.1016/j.celrep.2022.110639

Expression of the mono-ADP-ribosyltransferase ART1 by tumor cells mediates immune resistance in non-small cell lung cancer
Wennerberg, E, Mukherjee, S, Spada, S, Hung, C, Agrusa, CJ, Chen, C, Valeta-Magara, A, Rudqvist, NP, Van Nest, SJ, Kamel, MK, Nasar, A, Narula, N, Mittal, V, Markowitz, GJ, Zhou, XK, Adusumilli, PS, Borczuk, AC, White, TE, Khan, AG, Balderes, PJ, Lorenz, IC, Altorki, N, Demaria, S, McGraw, TE & Stiles, BM 2022, , Science translational medicine, vol. 14, no. 636, abe8195. https://doi.org/10.1126/scitranslmed.abe8195

Author Correction: Radiation-activated secretory proteins of Scgb1a1 + club cells increase the efficacy of immune checkpoint blockade in lung cancer (Nature Cancer, (2021), 2, 9, (919-931), 10.1038/s43018-021-00245-1)
Ban, Y, Markowitz, GJ, Zou, Y, Ramchandani, D, Kraynak, J, Sheng, J, Lee, SB, Wong, STC, Altorki, NK, Gao, D & Mittal, V 2022, , Nature Cancer, vol. 3, no. 2, pp. 262. https://doi.org/10.1038/s43018-022-00330-z

Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer
Liu, YL, Bager, CL, Willumsen, N, Ramchandani, D, Kornhauser, N, Ling, L, Cobham, M, Andreopoulou, E, Cigler, T, Moore, A, LaPolla, D, Fitzpatrick, V, Ward, M, Warren, JD, Fischbach, C, Mittal, V & Vahdat, LT 2021, , npj Breast Cancer, vol. 7, no. 1, 108. https://doi.org/10.1038/s41523-021-00313-w

Copper depletion modulates mitochondrial oxidative phosphorylation to impair triple negative breast cancer metastasis
Ramchandani, D, Berisa, M, Tavarez, DA, Li, Z, Miele, M, Bai, Y, Lee, SB, Ban, Y, Dephoure, N, Hendrickson, RC, Cloonan, SM, Gao, D, Cross, JR, Vahdat, LT & Mittal, V 2021, , Nature Communications, vol. 12, no. 1, 7311. https://doi.org/10.1038/s41467-021-27559-z

The metabolic adaptation evoked by arginine enhances the effect of radiation in brain metastases
Marullo, R, Castro, M, Yomtoubian, S, Nieves Calvo-Vidal, M, Revuelta, MV, Krumsiek, J, Cho, A, Morgado, PC, Yang, SN, Medina, V, Roth, BM, Bonomi, M, Keshari, KR, Mittal, V, Navigante, A & Cerchietti, L 2021, , Science advances, vol. 7, no. 45, eabg1964. https://doi.org/10.1126/sciadv.abg1964

Radiation-activated secretory proteins of Scgb1a1 + club cells increase the efficacy of immune checkpoint blockade in lung cancer
Ban, Y, Markowitz, GJ, Zou, Y, Ramchandani, D, Kraynak, J, Sheng, J, Lee, SB, Wong, STC, Altorki, NK, Gao, D & Mittal, V 2021, , Nature Cancer, vol. 2, no. 9, pp. 919-931. https://doi.org/10.1038/s43018-021-00245-1

Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity
Chow, A, Schad, S, Green, MD, Hellmann, MD, Allaj, V, Ceglia, N, Zago, G, Shah, NS, Sharma, SK, Mattar, M, Chan, J, Rizvi, H, Zhong, H, Liu, C, Bykov, Y, Zamarin, D, Shi, H, Budhu, S, Wohlhieter, C, Uddin, F, Gupta, A, Khodos, I, Waninger, JJ, Qin, A, Markowitz, GJ, Mittal, V, Balachandran, V, Durham, JN, Le, DT, Zou, W, Shah, SP, McPherson, A, Panageas, K, Lewis, JS, Perry, JSA, de Stanchina, E, Sen, T, Poirier, JT, Wolchok, JD, Rudin, CM & Merghoub, T 2021, , Cancer Cell, vol. 39, no. 7, pp. 973-988.e9. https://doi.org/10.1016/j.ccell.2021.05.006

Connecting copper and cancer: from transition metal signalling to metalloplasia
Ge, EJ, Bush, AI, Casini, A, Cobine, PA, Cross, JR, DeNicola, GM, Dou, QP, Franz, KJ, Gohil, VM, Gupta, S, Kaler, SG, Lutsenko, S, Mittal, V, Petris, MJ, Polishchuk, R, Ralle, M, Schilsky, ML, Tonks, NK, Vahdat, LT, Van Aelst, L, Xi, D, Yuan, P, Brady, DC & Chang, CJ 2022, , Nature Reviews Cancer, vol. 22, no. 2, pp. 102-113. https://doi.org/10.1038/s41568-021-00417-2

EMT process in bone metastasis
Gao, D, Zhang, XHF, Thompson, EW & Mittal, V 2021, . in Bone Cancer: Bone Sarcomas and Bone Metastases - From Bench to Bedside. Elsevier, pp. 359-370. https://doi.org/10.1016/B978-0-12-821666-8.00009-8

Erratum: Influencing the tumor microenvironment: A phase II study of copper depletion using tetrathiomolybdate in patients with breast cancer at high risk for recurrence and in preclinical models of lung metastases (Clinical Cancer Research (2017) 23 (666-676) DOI: 10.1158/1078-0432.CCR-16-1326)
Chan, N, Willis, A, Kornhauser, N, Ward, MM, Lee, SB, Nackos, E, Seo, BR, Chuang, E, Cigler, T, Moore, A, Donovan, D, Cobham, MV, Fitzpatrick, V, Schneider, S, Wiener, A, Guillaume-Abraham, J, Aljom, E, Zelkowitz, R, Warren, JD, Lane, ME, Fischbach, C, Mittal, V & Vahdat, L 2020, , Clinical Cancer Research, vol. 26, no. 18, pp. 5051. https://doi.org/10.1158/1078-0432.CCR-20-3177

Three-dimensional growth of breast cancer cells potentiates the anti-tumor effects of unacylated ghrelin and azp-531
Au, CC, Furness, JB, Britt, K, Oshchepkova, S, Ladumor, H, Soo, KY, Callaghan, B, Gerard, C, Inghirami, G, Mittal, V, Wang, Y, Huang, XY, Spector, JA, Andreopoulou, E, Zumbo, P, Betel, D, Dow, L & Brown, KA 2020, , eLife, vol. 9, e56913, pp. 1-27. https://doi.org/10.7554/eLife.56913

Unacylated ghrelin and AZP531 suppress the 3D growth of breast cancers
Au, CMC, Furness, JB, Britt, K, Oshchepkova, S, Ladumor, H, Soo, KY, Callaghan, B, Gérard, C, Inghirami, G, Mittal, V, Wang, Y, Huang, XY, Spector, JA, Andreopoulou, E, Zumbo, P, Betel, D, Dow, LE & Brown, KA 2020, , Unknown Journal. https://doi.org/10.1101/2020.01.22.915744

Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer
Yomtoubian, S, Lee, SB, Verma, A, Izzo, F, Markowitz, G, Choi, H, Cerchietti, L, Vahdat, L, Brown, KA, Andreopoulou, E, Elemento, O, Chang, J, Inghirami, G, Gao, D, Ryu, S & Mittal, V 2020, , Cell Reports, vol. 30, no. 3, pp. 755-770.e6. https://doi.org/10.1016/j.celrep.2019.12.056

Thrombospondin in Tumor Microenvironment
Ramchandani, D & Mittal, V 2020, . in Advances in Experimental Medicine and Biology. Advances in Experimental Medicine and Biology, vol. 1272, Springer, pp. 133-147. https://doi.org/10.1007/978-3-030-48457-6_8

Nanoparticle delivery of miR-708 mimetic impairs breast cancer metastasis
Ramchandani, D, Lee, SK, Yomtoubian, S, Han, MS, Tung, CH & Mittal, V 2019, , Molecular Cancer Therapeutics, vol. 18, no. 3, pp. 579-591. https://doi.org/10.1158/1535-7163.MCT-18-0702

The lung microenvironment: an important regulator of tumour growth and metastasis
Altorki, NK, Markowitz, GJ, Gao, D, Port, JL, Saxena, A, Stiles, B, McGraw, T & Mittal, V 2019, , Nature Reviews Cancer, vol. 19, no. 1, pp. 9-31. https://doi.org/10.1038/s41568-018-0081-9

Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival
Markowitz, GJ, Havel, LS, Crowley, MJ, Ban, Y, Lee, SB, Thalappillil, JS, Narula, N, Bhinder, B, Elemento, O, Wong, ST, Gao, D, Altorki, NK & Mittal, V 2018, , JCI insight, vol. 3, no. 13. https://doi.org/10.1172/jci.insight.96836

Epithelial Mesenchymal Transition in Tumor Metastasis
Mittal, V 2018, , Annual Review of Pathology: Mechanisms of Disease, vol. 13, pp. 395-412. https://doi.org/10.1146/annurev-pathol-020117-043854

Metastatic tumor cells – genotypes and phenotypes
Gao, D, Mittal, V, Ban, Y, Lourenco, AR, Yomtoubian, S & Lee, S 2018, , Frontiers in Biology, vol. 13, no. 4, pp. 277-286. https://doi.org/10.1007/s11515-018-1513-3